FDA panel to review Solvay cilansetron
Executive Summary
FDA's Gastrointestinal Drugs and Drug Safety & Risk Management Advisory Committees are expected to discuss Solvay's NDA for the irritable bowel syndrome treatment cilansetron at a joint meeting, the company says. The committees are tentatively scheduled to meet jointly on March 9. FDA has extended its review of cilansetron by 90 days to April 1, 2005; the proposed trade name for the drug is Calmactin (1"The Pink Sheet" May 24, 2004, p. 32)...
You may also be interested in...
Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.